Here’s Why Ford Stock Is Falling Today

Ford Motor Company (NYSE: F) shares are trading lower by 2.93% to $11.22 Wednesday. Stocks across sectors are trading lower after CPI data showed worse-than-expected June inflation. A rise in inflation has caused concerns of a potential recession and more aggressive Federal Reserve policy.

Ford Motor Company (NYSE:F) shares are trading lower by 2.93% to $11.22 Wednesday. Stocks across sectors are trading lower after CPI data showed worse-than-expected June inflation. A rise in inflation has caused concerns of a potential recession and more aggressive Federal Reserve policy.

The Consumer Price Index for All Urban Consumers (CPI-U) increased 1.3% in June on a seasonally adjusted basis after rising 1.0% in May, the U.S. Bureau of Labor Statistics (BLS) reported today. The BLS says the increase was broad-based, with the indexes for gasoline, shelter, and food being the largest contributors.

The BLS says the all items index increased 9.1% for the 12 months ending June, the largest 12-month increase since the period ending November 1981. The energy index rose 41.6% over the last year, the largest 12-month increase since the period ending April 1980.

The BLS added that while almost all major component indexes increased over the month, among the largest contributors were the indexes for used cars and trucks, motor vehicle insurance and new vehicles.

See Also: This Advertising Company Has A Better 5-Year Return Than Bitcoin, Ethereum, Starbucks, Ford, Microsoft, Apple, Disney And Amazon

According to data from Benzinga Pro, Ford has a 52-week high of $25.87 and a 52-week low of $10.61.

Total
0
Shares
Related Posts
Read More

Infection-Focused Barinthus Bio’s VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives

Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.

BRNS

Read More

What’s Going On With Revolution Medicines Stock?

Revolution Medicines announced the publication of a peer-reviewed research paper in "Cancer Discovery" detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The company also announced the publication of two peer-reviewed research papers in "Nature" Tuesday. The first paper highlights the discovery and preclinical characterization of RMC-7977, and the second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.

RVMD